An open label biomarker pilot study of the antitumoral acrivity of denosumab in the pre-operative setting of early breast cancer
Phase of Trial: Phase 0
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Early breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms D-BIOMARK
- 06 Aug 2019 Planned End Date changed from 5 Feb 2020 to 5 Feb 2021.
- 06 Aug 2019 Planned primary completion date changed from 5 Jul 2019 to 5 Jul 2020.
- 15 Jun 2018 New trial record